Chemoradiation analysis

Chemoradiation analysis from this patient's measured tumor state. Vary radiation dose and alkylating-agent exposure within the supported range and follow the compartment response over 24 weeks.

Week 0 of treatment

—

Observed scan

Drag to rotate

Outside the supported rangeThis dose combination lies outside the declared evaluation range, so ABP returns no response calculation.

Enhancing tumorNecrotic coreEdema / FLAIRDashed circle: size reference

Weeks since treatment start0

1 · Starting point

The analysis starts from a measured scan of this patient. The default is the scan obtained just after her first resection.

2 · Regimen

Radiation dose60 Gy60 Gy is the conventional course for glioblastoma. Chemotherapy exposure0.70Alkylating agent (temozolomide-class), relative scale 0–1.

3 · Support for this regimen

Each point is a dose combination. Green: within the supported evaluation range. Yellow: boundary range. Red: outside the evaluation range, where no response calculation is returned. Tap the map to select a regimen.

4 · Response at this week

	Start	This regimen	No treatment
Enhancing
Necrotic
Edema / FLAIR
Total

Treatment-related change

T2/FLAIR abnormality

Course over 24 weeks (cm³)

Total, this regimenEnhancing, this regimenDashed: no treatment

5 · Regimen search

Method and provenance

What the ratings do not include. RANO requires a stable or decreasing corticosteroid dose for a response to count. RANO 2.0 requires confirmation of objective response (after at least four weeks) and requires or recommends confirmation of progression in specified settings, particularly within 12 weeks of radiotherapy because of pseudoprogression. LUMIERE records neither steroid dose nor confirmation status. The ratings shown are the source dataset’s expert RANO labels and have not been re-adjudicated under RANO 2.0; read them as imaging assessments only.
Zoom and cut-away (pinch, the + and − buttons, or the mouse wheel after clicking the view; ◐ slices the tumor open) enlarge the current 3-D view to show how its compartments nest. They do not reveal detail finer than the MRI, whose resolution is on the millimetre scale.
Cells (✺ switches between cells and measurement dots) are illustrative renderings in the style of fluorescence microscopy, not imaged cells. Magenta cells are tumor cells: rounded in the tumor body, elongated where they infiltrate the surrounding edema, and shown dividing at a rate that rises when the enhancing tumor is growing. Grey, fragmenting cells are dying; they increase when the enhancing tumor shrinks or the necrotic core grows. Pale blue cells with branching processes are healthy brain cells around and among the infiltrating tumor cells. Infiltrating cells spread outward faster when edema is growing. The rates come from the displayed volumes (observed between scans, or calculated in the intervention analyses); the line under the legend states them. Zooming in brings the cells forward and fades the outlines.
Starting volumes are the measured LUMIERE Patient-067 compartments at the chosen scan (Suter et al., Scientific Data 9:768, 2022).
Patient anatomy. The 3-D view starts from Patient-067's measured tumor compartments and brain surface at the selected scan, reconstructed from LUMIERE's atlas-space DeepBraTumIA segmentation and simplified for display. Response calculations change compartment volumes around those measured centroids. LUMIERE does not record chemoradiation schedules, so dose-response values are calculated from the stated functions rather than read from this patient's treatment record. The Geometry control switches to equivalent-volume geometry.
Radiation response uses a linear-quadratic term; chemotherapy uses a Hill exposure-response term; the two combine with a synergy term. Untreated growth uses the stated doubling rate. The displayed dose-response calculation is literature-informed and is not taken from a recorded LUMIERE treatment schedule.
The support map defines the evaluation range: ≤66 Gy and exposure ≤0.80 is supported; up to 72 Gy and 0.90 is boundary; beyond that ABP returns no response calculation.
The regimen search scans a dose grid inside the supported and boundary regions and reports the lowest value for the selected objective within that range.